Background. Catheter-related bloodstream infection (CRBSI) causes substantial morbidity and mortality, but few randomized, controlled studies have been conducted to guide therapeutic interventions.
Linezolid was considered for study in CRBSI because of activity against staphylococci, enterococci, and other grampositive bacteria, including those resistant to methicillin and vancomycin [14] . Linezolid is approved by the US Food and Drug Administration (FDA) for MRSA infection and can be administered orally and intravenously. Randomized effi acy and safety studies have been published that compare linezolid with vancomycin in patients with serious infections, such as complicated skin and skin-structure infections (cSSSIs) [15] , MRSA infection [16] , febrile neutropenia [17] , and nosocomial pneumonia [18, 19] , including the subsets with bacteremia [20] .
To test the hypothesis that linezolid would be noninferior to vancomycin for catheter-related infection, we conducted a randomized, controlled, prospective study. Two patient populations with microbiologic end points were define a priori for primary analysis. The rationale for choosing the homogeneous bacteremic population was based on the 1999 Draft Guidance from the FDA [20] . Preliminary study results were presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy [21] and posted on a clinical trial registry [22] .
METHODS
Eligibility criteria. Adults (age, у13 years; weight, у40 kg) who had a central venous, pulmonary artery, or arterial catheter in place for 13 days and suspected catheter-related infection were eligible for participation in the study. Suspicion of infection was based on signs and symptoms. Patients with S. aureus bacteremia were to undergo echocardiography to rule out endocarditis. Exclusion criteria were intravascular catheter that could not be removed for culturing, endovascular or other infection likely to result in bacteremia, permanent intravascular device infection, treatment contraindication, treatment with an active antibiotic within 72 h before study entry, or underlying condition that would interfere with assessment (e.g., infection with another gram-positive organism or likelihood that catheter removal would obviate antibacterial treatment or that the patient would not survive).
The study was approved by the investigators' institutional review boards or independent ethics committees. Patients or their legal representatives were required to provide valid written informed consent.
Interventions. Patients were randomly assigned in a 1:1 ratio to receive linezolid, 600 mg, or vancomycin, 1 g, each administered intravenously every 12 h for 7-28 days. Stratifcation was based on catheter type and duration of placement before enrollment. All catheters were removed. After the f rst linezolid dose, the same dose could be administered orally. Vancomycin dose could be adjusted for renal function according to local practice. For methicillin-susceptible pathogens, vancomycin could be switched to oxacillin, 2 g intravenously, or dicloxacillin, 500 mg orally, each given every 6 h.
For suspected infections with gram-negative organisms, aztreonam or amikacin was recommended, whereas for documented gram-negative anaerobic, fungal, and viral infections, concomitant therapy was allowed on the basis of susceptibility and local practice.
Assessment of response and safety. Patients were assessed at enrollment (baseline), during therapy, and at the end of treatment (EOT), TOC 1-2 weeks after treatment, and longterm follow-up 6-8 weeks after treatment. Physical examination and Mortality Probability Model II scoring [23] were performed at baseline. Signs and symptoms of catheter-related infection, vital signs, hematologic test results, and serum chemical test results were assessed at baseline; on days 3, 7, 14, and 21; and at EOT, TOC, and long-term follow-up. Samples were obtained from peripheral blood, catheter blood, catheter-site exudates, and aspirate of catheter-site cellulitis at baseline and, if obtainable, EOT, TOC, and long-term follow-up. Isolates were sent to a central laboratory (Covance; Indianapolis, IN) for culture and susceptibility testing according to 2002 Clinical Laboratory Standards Institute guidelines (M100-S12; the latest are posted at http://www.clsi.org) and for DNA f ngerprinting by PFGE. Patients with S. aureus were assessed for metastatic infection at long-term follow-up, with physical examination and vital signs measurement, laboratory studies, culture of peripheral blood, catheter-site exudate and cellulitis (if culture material is obtainable), and echocardiography (if indicated). Safety was monitored through long-term follow-up. Figure 1 shows the criteria for patient analysis populations. In the second microbiologically evaluable (ME-2) group, CRBSI was define as positive peripheral blood culture result and isolation of the same pathogen from catheter blood, catheter tip, or exit-site exudates, according to FDA guidance [24] and quantitative or semiquantitative catheter-tip culturing methods [25, 26] . The firs modifie microbiologically evaluable (MME-1) population included patients with cSSSI due to gram-positive pathogens associated with an indwelling catheter. The MME-1 population included ME-1 patients who had baseline grampositive pathogens other than coagulase-negative staphylococci recovered from any valid culture source or any coagulasenegative staphylococci species for which there was 11 isolate from a valid culture source (у2 being concordant) and у1 of these concordant isolates was cultured from a source other than the catheter tip. The intent-to-treat (ITT) population included all randomized patients who received the firs dose of study medication; the modifie ITT (MITT) population was the microbiology subset of the ITT population with a gram-positive organism isolated at baseline.
The primary end point, microbiologic outcome in MME-1 and ME-2 at TOC, was assessed as success (documented or presumed eradication based on clinical outcome) or failure (documented or presumed persistence based on clinical failure 2 test beginning with complicated skin and skin-structure infection (cSSSI) in the first modified microbiologically evaluable (MME-1) population and, if noninferiority criteria were met, followed by catheter-related bloodstream infection (CRBSI) in the second microbiologically evaluable (ME-2) population. CoNS, coagulase-negative staphylococci; CRSBI, catheter-related bloodstream infection; ITT, intent to treat. and either missing microbiologic outcome or use of nonstudy antibiotic because of lack of efficacy) The secondary end point, clinical outcome at TOC, was assessed as success (cure with resolution of signs and symptoms or, at EOT only, improvement with moderate resolution of signs and symptoms and no additional antibiotic treatment) or failure (persistence or progression of clinical signs and symptoms or new clinical fi dings of infection). At least 5 days of study drug were required for an assessment of clinical success and у3 days for clinical failure.
Data analysis. Two hundred ninety-four (147 per group) ME patients were required to determine noninferiority (lower bound of at least Ϫ15% for 95% CI around the difference) on the basis of a 2-sided test with an a level of .05 and statistical power of 80%, assuming a 70% microbiologic success rate. After enrollment, but before results were examined and in consultation with a regulatory authority [27] , the analysis plan was amended to designate MME-1 with cSSSI as the firs analysis population to be tested (figu e 1). The primary eff cacy end point was assessed by a step-down procedure beginning with cSSSI and, if noninferiority criteria were met, followed by CRBSI. Both analyses excluded missing or indeterminate outcomes; sensitivity analyses were performed counting these as failures. To assess adequacy of treatment in patients with baseline gram-negative organisms, 2 academic physicians performed an independent blinded review. Adequate treatment was define as у1 antibiotic active against the organism within 24 h of culture. Treatment comparisons for categorical (binary) variables were assessed using the Pearson x 2 tests, with data summaries comprising frequencies, percentages, and 95% CIs for between-group differences. The 95% CIs were based on normal approximation to the binomial, assuming independence and unequal variances between groups. Continuous variables were summarized using mean, SD, and range. Descriptive mortality summaries were presented comprising frequencies, percentages, and Kaplan-Meier curves. Comparisons were assessed using point estimates and 95% CIs for the hazard ratio. Statistical output was generated with SAS statistical software, version 8.2 (SAS).
RESULTS

Seven hundred thirty-nine patients were enrolled at 100 centers from May 2002 through May 2005 (figu e 1)
. Four were excluded because of data inaccuracies and lack of source documentation. Nine received no study medication and were excluded from the ITT analysis. The remaining 726 were from Europe ( ), the United States ( ), Latin America n p 270 n p 221 ( ), and Asia ( ). Three hundred ninety-three n p 201 n p 34 completed treatment. Discontinuation reasons were no grampositive pathogen (linezolid group, 70 patients; control group, 77), adverse event (linezolid group, 48; control group, 25), lack of efficac (linezolid group, 25; control group, 28), protocol violation (linezolid group, 15; control group, 23), loss to followup (linezolid group, 6; control group, 6), and withdrawal of consent (linezolid group, 6; control group, 4). One hundred eight patients had protocol violations, usually prohibited nonstudy medication (linezolid group, 21; control group, 25) or wrong strata assignment for catheter type or duration (linezolid group, 24; control group, 21); these patients were analyzed according to actual strata.
Baseline characteristics were similar between groups (table  1) . Nearly 90% of patients had central venous catheters in place, usually in subclavian or internal jugular veins. The median duration of placement was 10 days (10 days for the linezolid group and 11 days for the control group); 19% of patients had catheters in place for 128 days (18.8% in the linezolid group and 19.1% in the control group). The mean Mortality Probability Model II score was 13.6 for the linezolid group and 13.1 for the control group. The most common pathogens were S. aureus and coagulase-negative staphylococci, which were methicillin resistant in 67% of patients (table 2). All isolates were susceptible to both agents, except for 7 vancomycin-resistant enterococci isolates; these patients were excluded from the ME-1 population. No gram-positive bacteria developed resistance to either agent during the study. Microbiologic outcome. Microbiologic outcomes at TOC met noninferiority criteria in the 2 primary analysis populations (table 3). In the subset with cSSSI (MME-1), success occurred in 146 (89.6%) of 163 linezolid patients and in 134 (89.9%) of 149 control patients (95% CI, Ϫ7.1 to 6.4). Eight of 32 microbiologic failures were documented; 24 were presumed. Six linezolid patients had persistent MRSA ( ), methicillinn p 4 susceptible S. aureus ( ),orEnterococcus faecalis ( ). n p 1 n p 1 Two control patients had persistent infection with E. faecalis alone ( ) or with S. aureus and Staphylococcus epidermidis n p 1 ( ). In addition to documented persistence as an outcome n p 1 at TOC, 22 linezolid recipients and 24 control patients had persistent infections after day 6, usually caused by S. aureus, which was isolated from peripheral blood specimens.
In the subset with CRBSI (ME-2), microbiologic success occurred in 82 (86.3%) of 95 linezolid recipients and in 67 (90.5%) of 74 control patients (95% CI, Ϫ13.8 to 5.4). Four of 20 microbiologic failures were documented; the failures occurred among linezolid recipients, were caused by MRSA ( )orE. faecalis ( ), and occurred on study days 7, n p 3 n p 1 7, 8, and 19. Baseline MIC values for persistent gram-positive bacteria were usually 2 mg/mL for linezolid and 1 mg/mL for vancomycin. Sensitivity analysis, with indeterminate and missing outcomes considered persistence, did not alter microbiologic outcomes in the MITT population.
Fifteen patients with baseline S. aureus infection had possible metastatic sequelae at long-term follow-up. Of 8 linezolid recipients, 3 had metastatic infections, including 1 case each of endocarditis, osteomyelitis, and septic phlebitis or thrombophlebitis; 3 had unspecifie or unknown metastatic infections; and 2 had microbiologically unconfi med infections. Of 7 control patients, 2 had septic phlebitis or thrombophlebitis alone ( ) or with osteomyelitis ( ), 4 had unspecif ed or n p 1 n p 1 unknown metastatic infections, and 1 had microbiologically unconfi med infection. Four patients (linezolid group, 3; control group, 1) had documented vegetation р7 days after enrollment. The control patient was excluded from analysis because of negative culture results; the linezolid recipients were included in the MITT and other relevant populations.
Clinical outcome. In the secondary end point analysis, the subset with cSSSI at TOC ( (%) of patients assessed, unless otherwise indicated. Percentages were based on number of patients assessed and excluded patients with indeterminate or missing outcomes. ME, microbiologically evaluable; MME, modified microbiologically evaluable; SSSI, skin and skinstructure infection. and 230 control patients (63.4%; table 5). The most common treatment-related adverse events of any severity were gastrointestinal disturbances; nausea was more frequently reported in linezolid recipients than among control subjects. Most of these events were considered to be unrelated to treatment and were of mild-to-moderate severity. Eleven patients had severe treatment-related events. Six linezolid recipients had severe events comprising allergic reaction, bronchospasm, diarrhea, hypertension, lack of efficac , and thrombocytopenia. Five control patients had severe events comprising allergic reaction, Clostridium difficil colitis, diarrhea, dizziness, nausea, and rash (1 patient had 2 severe events). The only reports of myelosuppression considered to be treatment related occurred in the linezolid group (5 of 31 cases). Three patients developed thrombocytopenia, which was confounded by heparin use ( ) n p 2 or recent history of anemia and gastrointestinal bleeding ( ). Two patients developed leukopenia, including 1 of the n p 1 patients who also had thrombocytopenia.
Four patients had visual adverse events (linezolid group, 3; control group, 1). The single visual event considered to be treatment related was blurred vision on day 2 of linezolid treatment, and it reversed in 2 days without treatment interruption. Three patients developed possible peripheral neuropathy (linezolid group, 2; control group, 1). The only case considered to be treatment related was paresthesia on day 2 of linezolid treatment, and it reversed after discontinuation of linezolid therapy.
Analysis of mean hematologic laboratory data at EOT, immediately after maximum exposure to study drug, revealed no clinically important between-group changes from baseline in hemoglobin concentration or in WBC or platelet counts. More linezolid recipients than control patients had substantially ab- normal platelet values, define as values !75% of the lower limit of normal or baseline value at EOT (linezolid group, 13.1%; control group, 7.4%). Similar proportions of patients had platelet counts of !50,000 platelets/mm 3 during the study (linezolid group, 9.8%; control group, 8.3%).
Mortality in the MITT population through TOC occurred in 28 (10.4%) of 269 linezolid patients and 26 (10.1%) of 257 control patients. In the subset with CRBSI, 1 linezolid patient and 3 control patients had died by TOC. The 3 control patients had S. aureus bacteremia, which was due to a methicillin-resistant isolate in 1 patient; none of the deaths were considered to be treatment related by the investigators. When the analysis was extended through posttreatment day 84 to include all treated patients (ITT), mortality occurred in 78 (21.5%) of 363 linezolid recipients and 58 (16.0%) of 363 control patients (95% CI, Ϫ0.2 to 11.2). Kaplan-Meier survival curves showed an excess of deaths among linezolid recipients with negative culture results or gram-negative bacteremia only at baseline and in control patients with S. aureus bacteremia at baseline (figu es 2 and 3). MRSA was present in 63 (44%) of 142 patients with S. aureus bacteremia, and of the 30 deaths, 17 occurred in patients with MRSA bacteremia (linezolid group, 9; control group, 8). Independent blinded review of patients with gramnegative bacteremia revealed that treatment was adequate in 22 (37%) of 59 linezolid recipients and 19 (40%) of 47 control patients.
DISCUSSION
To our knowledge, this was the largest randomized study of patients with CRBSI to date. Most patients had serious underlying disease that required central venous catheterization; almost one-half had been in intensive care units. Predefine noninferiority criteria were met for cSSSI, with microbiologic response rates of 90% in both groups. These response rates may not be comparable with those in studies using traditional diagnostic criteria, because our criteria were intended to select for CRBSI. Predefine noninferiority criteria were also met for CRBSI.
The other randomized study of linezolid treatment in patients with gram-positive bacteremia [28] used teicoplanin as a control agent and revealed microbiologic success rates of 76% for linezolid (13 of 17 patients) and 55% for teicoplanin (12 of 22; ) [28] . Between-study comparisons of response P p .16 rates, however, are limited by differences in study design, patient population, and sample size. In our study, both regimens appeared to be well tolerated on the basis of the low incidence of treatment discontinuations associated with adverse events. The frequency and severity of adverse events were generally similar between groups, with the exception of gastrointestinal disturbances due to oral linezolid administration. Patients were carefully monitored for adverse events previously described with linezolid. Consistent with a recent meta-analysis [29] , there was a difference in abnormal platelet counts, with 5 reports of drug-related myelosuppression in linezolid recipients. There was no evidence of an increased incidence of lactic acidosis, peripheral neuropathy, or optic neuropathy, which is not surprising, because previous reports have been limited to anecdotal case reports and, usually, longterm treatment [30] . The mortality imbalance in the analysis of all patients through posttreatment day 84 (linezolid group, 21.5%; control group, 16.0%) was unexpected in view of the similar rates in the MITT population at TOC (linezolid group, 10.4%; control group, 10.1%). Much of the imbalance occurred in patients infected with gram-negative pathogens or who had negative culture results at baseline and not in the primary analysis population with gram-positive pathogens and particularly those with S. aureus infections. To further investigate the imbalance, we assessed treatment for infection with gram-negative pathogens and showed that fewer than one-half of patients in both groups received potentially effective treatment. The posthoc nature of these analyses and the size of these subsets of the primary analysis populations limit certainty, yet they provide future study opportunities. Additional analyses to assess mortality imbalance factors, such as synergy and antagonism analyses using organisms isolated from study patients, effect on cytokine production, and effect on neutrophil function, have shown no adverse effect with linezolid.
This study had several limitations. Open-label studies have the potential for bias; however, the primary end point was microbiologic outcome. When culture specimens were not obtained, microbiologic outcome was based on a surrogate end point, clinical outcome. In addition, the protocol specif ed a vancomycin dosage of 1 g every 12 h, which was standard and recommended by leading textbooks [31, 32] when the study began. We did not specify therapeutic targets or collect vancomycin levels but allowed dosage adjustment as necessary. Paradoxically, this protocol-specifie dosage was higher than that calculated by the Matzke method using estimated renal clearance and mean patient weights from this study [33] .
The study had fewer patients with CRBSI than with cSSSI. We estimated that a study powered for CRBSI would have required screening ∼26,000 patients [27] . Despite this, there was consistency in the finding among several outcome populations, including microbiologic outcome in the primary efficac end points, clinical outcomes at EOT and TOC in patients with S. aureus cSSSIs and CRBSIs, and mortality in patients with S. aureus bacteremia at baseline.
In conclusion, the results of this randomized, open-label, phase 3 study demonstrated that linezolid was noninferior to vancomycin and other control regimens in patients with cSSSI or CRBSI due to gram-positive organisms. Although causality has not been established, the mortality imbalance underscores the need to carefully monitor patients with suspected bacteremia and to promptly initiate appropriate treatment, especially in patients with suspected infection with gram-negative pathogens.
